Patient preferences for rheumatoid arthritis treatments: results from the national cross-sectional LERACS study
Authors Fayad F, Ziade NR, Merheb G, Attoui S, Aiko A, Mroue K, Masri AF
Received 3 May 2018
Accepted for publication 17 July 2018
Published 31 August 2018 Volume 2018:12 Pages 1619—1625
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Johnny Chen
Fouad Fayad,1 Nelly R Ziade,1 Georges Merheb,2 Said Attoui,3 Alla Aiko,4 Kamel Mroue,3 Abdel Fattah Masri5
1Rheumatology Department, Hotel Dieu de France Hospital, Saint Joseph University, Beirut, Lebanon; 2Department of Rheumatology, Notre Dame des Secours University Hospital, Jbeil, Lebanon, Holy Spirit University, Kaslik, Lebanon; 3Rheumatology Department, Hammoud University Medical Center, Saida, Lebanon; 4Department of Medicine (Rheumatology), Saint George Hospital, Beirut, Lebanon; 5Department of Internal Medicine (Rheumatology), American University of Beirut Medical Center, Beirut, Lebanon
Introduction: To investigate the treatment preferences of patients with rheumatoid arthritis (RA) and determine whether these preferences are related to specific disease characteristics.
Method: A national survey was designed to collect demographic, disease, treatment, and preference data on RA patients enrolled in 7 private and university hospital clinics in Lebanon. Associations between patient factors and treatment preferences for RA were analyzed by χ2 or Mann–Whitney U test.
Results: A total of 693 patients (83% female; 67% aged 41–70 years) consulting 7 trained rheumatologists completed the survey. Most patients (80%) had established RA >24 months, and approximately one-third (34%) were in remission according to the disease activity score in 28 joints (DAS28). Most (87%) were receiving oral agents (60% oral only). Almost two-thirds of patients (64%) expressed a preference for oral treatments, and more than half (53%) ranked doctor’s advice as the most influential factor when choosing treatment. In univariable analysis, health coverage, radiographic damage, disease duration, current therapy, and previous side effects were significantly associated with treatment preference. In multivariable analyses, only radiographic damage and current route of administration were independently associated with preference (both P<0.001), with patients with no radiographic damage and those on oral-only therapy being more likely to prefer oral agents.
Conclusion: RA patients expressed a preference for oral rather than subcutaneous/intravenous-administered drugs. Understanding patients’ preferences may help to inform policymaker decisions.
Keywords: rheumatoid arthritis, administration, patient, preference
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]